| Original language | English (US) |
|---|---|
| Title of host publication | Biological Chemistry of Arsenic, Antimony and Bismuth |
| Publisher | John Wiley and Sons |
| Pages | 311-329 |
| Number of pages | 19 |
| ISBN (Print) | 9780470713907 |
| DOIs | |
| State | Published - Nov 15 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 213Bi and 212Bi, metallic in nature - chelation chemistry or bifunctional chelators for antibody linkage
- Cancer treatment, and surgery - external beam radiation therapy and chemotherapy
- Chemo-resistance and radio resistance - acquired by tumors, in conventional therapies
- Landmark clinical trial, Memorial Sloan-Kettering Cancer Center - 213Bi-labeled humanized anti-CD33 monoclonal antibody
- Monoclonal antibodies (mAbs) - viable strategy for therapeutic delivery
- Radiobismuth for therapy
- Radioimmunotherapy of experimental fungal, bacterial and viral infections - and 213bi-labeled antibodies
- Targeted a-therapy versus targeted b-therapy
- Targeted radiation therapy - stable sequestration of radionuclide in vivo, delivery of radiation to tumors
- Targeting vectors, Murine mAbs - against tumor associated antigens (TAA), and multitudes of preclinical studies
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS